ENDOSOMOLYTIC POLY(AMIDOAMINE) DISULFIDE POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES

1 . A polymer according to the Formula Z:

wherein:

n is 2 to 250;

R is independently selected from A, B and C, wherein at least two of A, B and C are present in the polymer and the polymer must include at least one cationic component (A or B) and at least one aliphatic component (B or C);

A is a first cationic component;

B is a second cationic component or a second aliphatic component; and

C is a first aliphatic component;

or stereoisomer thereof.

2 . A polymer according to claim 1 of the Formula Z:

wherein:

n is 2 to 250;

R is independently selected from A, B and C, wherein at least two of A, B and C are present in the polymer and the polymer must include at least one cationic component (A or B) and at least one aliphatic component (B or C);

A is a first cationic component selected from an amine (primary, secondary, tertiary or quaternary), a nitrogen heterocycle, an aldimine, a hydrazide and a hydrazone;

B is a second cationic component selected from an amine (primary, secondary, tertiary or quaternary), a nitrogen heterocycle, an aldimine, a hydrazide and a hydrazone, or a second aliphatic component; and

C is a first aliphatic component;

or stereoisomer thereof.

3 . A polymer according to claim 2 of the Formula Z:

wherein:

n is 2 to 250;

R is independently selected from A, B and C, wherein A, B and C are all present in the polymer;

A is 2-(2-aminoethoxy)ethyl;

B is 2-(1H-imidazol-4-yl)ethyl; and

C is dodecyl;

or a stereoisomer thereof.

4 . A polymer according to claim 1 of the Formula Z selected from

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 1;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 2;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 3;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 4;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 5;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 6;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 7;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 8;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 9;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 10;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 11;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 12;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 13;

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 14; and

wherein x, y and z are between 0 to 50 and the % ratios of substituents A, B and C are defined in Table 15;

or stereoisomer thereof.

5 . The polymer according to claim 1 of the Formula Z wherein substituents A, B and C are all present in the polymer and wherein A, B and C are different from one another.

6 . The polymer according to claim 1 of the Formula Z wherein substituent A must comprise at least 50% of the polymer.

7 . The polymer according to claim 1 of the Formula Z wherein substituent B must comprise at least 50% of the polymer.

8 . The polymer according to claim 1 of the Formula Z wherein substituent C must comprise at least 50% of the polymer.

9 . A composition comprising a polymer of Formula Z and an oligonucleotide.

10 . A composition according to claim 9 further comprising a masking agent.

11 . A composition according to claim 10 further comprising a targeting agent.

12 . A method of treating a disease in a patient by administering a composition of claim 9 .